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Abstract
Background: Autism is a complex childhood neurodevelopmental disorder with a strong genetic basis. Microdeletion or
duplication of a ,500–700-kb genomic rearrangement on 16p11.2 that contains 24 genes represents the second most
frequent chromosomal disorder associated with autism. The role of common and rare 16p11.2 sequence variants in autism
etiology is unknown.
Methodology/Principal Findings: To identify common 16p11.2 variants with a potential role in autism, we performed
association studies using existing data generated from three microarray platforms: Affymetrix 5.0 (777 families), Illumina
550 K (943 families), and Affymetrix 500 K (60 families). No common variants were identified that were significantly
associated with autism. To look for rare variants, we performed resequencing of coding and promoter regions for eight
candidate genes selected based on their known expression patterns and functions. In total, we identified 26 novel variants
in autism: 13 exonic (nine non-synonymous, three synonymous, and one untranslated region) and 13 promoter variants. We
found a significant association between autism and a coding variant in the seizure-related gene SEZ6L2 (12/1106 autism vs.
3/1161 controls; p=0.018). Sez6l2 expression in mouse embryos was restricted to the spinal cord and brain. SEZ6L2
expression in human fetal brain was highest in post-mitotic cortical layers, hippocampus, amygdala, and thalamus.
Association analysis of SEZ6L2 in an independent sample set failed to replicate our initial findings.
Conclusions/Significance:Wehaveidentified sequencevariationinatleastonecandidategenein16p11.2thatmayrepresent
a novel genetic risk factor for autism. However, further studies are required to substantiate these preliminary findings.
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Introduction
Autism (MIM 209850) is a phenotypically and etiologically
heterogeneous disorder of childhood characterized by impair-
ments in social interaction, deficits in verbal and non-verbal
communication, and restricted interests and repetitive behaviors.
Co-morbid features include mental retardation (occurrence ,30–
60%) [1], anxiety and mood disorders [2], and seizures (,20%)
[3]. Pathological and imaging studies indicate that structural brain
abnormalities and aberrant synaptic connectivity may underlie the
autism phenotype in some individuals [4,5]. Autism comprises the
severe end of a group of autism spectrum disorders (ASD), which
also include Asperger syndrome, pervasive developmental disorder
not otherwise specified (PDD-NOS), and rare syndromic forms
including Fragile X and Rett syndromes [6]. Prevalence rates for
autism and ASD are estimated at 0.2% and 0.6%, respectively,
and males are more likely than females to have a diagnosis of ASD
(male:female ratio<4:1) [7,8]. Twin and family-based studies
indicate a strong genetic basis for autism [9,10].
The frequency of microscopically visible structural chromosom-
al imbalances in autism is high and estimated at ,7% [11,12].
The most frequent abnormality is maternal duplication 15q11-13,
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observed cytogenetic abnormalities include deletions of 2q37,
22q11.2 and 22q13.3 [11,14]. Recently, submicroscopic copy
number variants (CNVs) not otherwise detectable using traditional
cytogenetic techniques have been identified using whole-genome
microarray-based approaches such as array comparative genomic
hybridization (aCGH) and high-density SNP genotyping platforms
[15–19]. Among these newly identified CNVs are microdeletions
of 16p11.2, which have been observed in ,0.5% of autism
patients [18,20,21] making this the second most common
chromosomal abnormality in autism. The reciprocal 16p11.2
microduplication has also been observed in ,0.5% of autism
patients, although the association is less convincing given a higher
frequency in control cohorts [18,20,21]. Interestingly, the
duplication has recently been found in ,2.4% of patients with
childhood-onset schizophrenia [22] as well as in ,0.07% patients
with bipolar disorder [21].
The 16p11.2 microdeletion/duplication spans ,500 kb and is
flanked by ,147-kb low copy repeats (LCRs) that are .99%
identical [20]. The intervening single copy sequence contains ,24
genes and the flanking 147-kb LCRs contain at least three genes.
Genomic losses (and possibly gains) at 16p11.2 could directly
contribute to the autism phenotype by affecting dosage-sensitive
genes in this region, disrupting genes at the breakpoints or
unmasking recessive mutations on the other allele. In patients
without these imbalances, functional sequence variants in one or
more genes in 16p11.2 may represent risk factors for autism.
Two hypotheses have been proposed for the contribution of
functional variants to common and complex human diseases such
as autism [23]. The common disease common variant (CDCV)
hypothesis postulates that common variants with small to modest
effects (allele frequencies .1%) may underlie susceptibility to
common disorders. Alternatively, the common disease rare variant
hypothesis (CDRV) suggests that susceptibility to common
disorders may be due to low frequency (,0.01% to ,1%) variants
with moderate to high penetrance located in one or more genes
[23]. The role of common and rare 16p11.2 sequence variants in
the complex etiology of autism has not been examined. We
therefore undertook a study of the 16p11.2 region to investigate
the role of genetic variation in eight candidate genes we
hypothesize may represent risk loci for autism spectrum disorders.
Results
Common genetic variation in 16p11.2
To assess whether common genetic variation at 16p11.2 might
be associated with autism, we performed a family-based
association analysis on two autism data sets that have recently
been generated using two whole-genome high-density single
nucleotide polymorphism (SNP) genotyping platforms. These
microarray studies were performed on 777 families from the
Autism Genetics Resource Exchange (AGRE) using the Affymetrix
5.0 array [21] and on 943 AGRE families using the Illumina
Hap550 microarray (www.agre.org/) (Bucan and Hakonarson,
unpublished). In addition, we analyzed data on 60 families
generated from the Affymetrix 500 K platform [18].
We performed two types of tests: a transmission disequilibrium
test (TDT) [24] with both parents genotyped and the DFAM test
[25] using all families. The TDT identified one nominally
significant association (p=0.049) with intragenic marker
rs7193756 (chr16:29,657,155-29,657,655) from the Affymetrix
5.0 data; however, the DFAM was not significant (p=0.20) (Table
S1). The association with rs7193756 and autism did not remain
significant after correcting for multiple comparisons (region-wide
p=0.3576). The closest annotated gene to this marker is the
transmembrane protein C16orf54 located ,4-kb downstream of
rs7193756. We used HapMap data (http://www.hapmap.org/) to
generate linkage disequilibrium (LD) structure around rs719376,
which indicated that it resides in an ,56-kb block defined by
markers rs9922666 and rs7205278 (chr16:29,605,876-
29,662,434) that contains the QPRT gene (data not shown).
Rare genetic variation in candidate 16p11.2 genes
We next addressed whether rare variants in 16p11.2 genes
represent risk factors for autism. We performed a literature review
ofthe24genesat16p11.2and selectedthefollowingeightcandidate
genes for mutation analysis based on biological function, genetic
mouse models, and expression data: ALDOA (NM_000034.2),
DOC2A (NM_003586.2), HIRIP3 (NM_003609.2), MAPK3
(NM_002746.2), MAZ (NM_002383.2), PPP4C (NM_002720.1),
SEZ6L2 (NM_201575.2), and TAOK2 (NM_004783.2) (Table S2).
For each of the eight candidate genes, we sequenced the coding
regions and their associated splice sites, 59 and 39 untranslated
regions (UTRs), and proximal promoter region (,1500 bp
upstream of the transcription start site) in an initial minimum
sampleof,100unrelated autismsubjects.Inparallel,wesequenced
all eight candidate genes in ,100 control subjects to assess the
natural genetic variation at these loci and to identify autism-specific
variants. We also sequenced these genes in five previously reported
patients with 16p11.2 microdeletions [20] to test the hypothesis that
microdeletions might unmask recessive alleles on the non-deleted
chromosome. In total, we identified 26 novel, autism-specific rare
variants, including 13 exonic and 13 promoter variants (Table 1). A
complete description of these variants, including demographic data
on patients, and conservation, transmission and segregation of each
variant, is presented in Table S3. We also identified 44 control-
specific variants in the eight genes examined (Table S4).
Genetic variation in SEZ6L2 is associated with autism
Our most interesting preliminary finding was a recurrent
autism-specific R386H amino acid substitution in exon 7 of the
seizure-related gene SEZ6L2 that we identified in our initial
mutation screen (4/93 autism and 0/93 controls). This association
was not significant with these low numbers but suggested a trend
(Fisher’s exact two tailed p=0.12). We determined inheritance
and segregation of R386H and demonstrated perfect segregation
of this variant with the autism phenotype in all four families. This
variant was not predicted to affect protein function using
PolyPhen; however, R386H results in a strongly basic (arginine)
to weakly basic (histidine) substitution in the CUB domain that is
found almost exclusively in extracellular and plasma membrane-
associated proteins, many of which are developmentally regulated
[26,27]. The R386 residue was conserved in 16 representative
mammalian species and was present as H386 in five representative
fish species (http://genome.ucsc.edu/; hg18). The overall initial
pattern of association and specificity to autism as well as the
potential role of SEZ6L2 in seizures (which are present in ,20% of
autism cases) warranted further analyses of this gene.
We undertook a case-control association analysis of R386H by
sequencing exon 7 in an additional 1013 autism patients and 1068
controls. The majority of these subjects were of European descent
(Table S5). Among all individuals studied, we found a statistically
significant association between R386H and autism (12/1106
autism versus 3/1161 controls; Fisher’s exact two tailed p=0.018).
All 15 subjects harboring R386H were of European descent. In all
cases, the variant was inherited with no bias between maternal
versus paternal transmission (Table S6).
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None of the probands or any of their affected siblings were
reported to have seizures. No common phenotypic features were
observed among subjects with R386H.
We performed a replication study of R386H in independent
autism and control cohorts, which failed to replicate our initial
findings (4/529 autism versus 9/570 control; Fishers exact two
tailed p=0.42). Unexpectedly, five of the nine controls carrying
the R386H variant had ancestry in the Orkney Islands, suggesting
a possible founder effect. When all families with ancestry from the
Orkneys were excluded from the control cohort, the findings were
still not replicated.
To look for additional rare variants in SEZ6L2, we sequenced
the remaining 16 exons in an additional 434 autism patients and
185 controls and identified seven autism-specific coding variants
(four non-synonymous and three synonymous) and two promoter
variants (Table 1). Examination of the autism-specific variants in
parents and affected and/or unaffected siblings demonstrated that
all variants were inherited. We identified a synonymous substitu-
tion in the middle of exon 2 (E38E) in a patient (HI2997)
previously reported to harbor a 16p11.2 microdeletion [20,21].
We cannot exclude the possibility that this substitution might affect
SEZ6L2 regulation, as synonymous mutations can occasionally
affect protein function by altering mRNA stability and protein
synthesis [28].
Mouse and human expression studies of SEZ6L2
We performed in situ hybridization studies of SEZ6L2 in mouse
embryos and human fetal brains. In mouse embryonic day 10.5
(e10.5) and e12.5 embryos, Sez6l2 expression was restricted to the
brain and spinal cord (Figure 1A–B). We also reviewed the
GENSAT mouse brain expression database (http://www.gensat.
org). At e15.5, Sez6l2 expression was highest in the olfactory bulb,
cerebellum, and brainstem; at postnatal day 7, expression was
widely distributed throughout the brain at low levels. Analyses of
human fetal brains (gestational weeks 16–19) showed high SEZ6L2
Table 1. Summary of exonic and promoter variants identified in autism.
Gene Location
a Amino Acid
b Nucleotide
c Genotype
d Chromosome
f Protein Prediction
g Autism Frequency
k Control Frequency
k
ALDOA 59 UTR na 123244G.A Het chr16:29974016 na 1/86 0/92
DOC2A Pro2 na 77883G.A Hom chr16:29930371 na 1/85 0/89
DOC2A Exon 6 M225I 82362G.A Het chr16:29925892 Possibly damaging 1/176 0/258
DOC2A Exon 7 R266Q 82566G.A Het chr16:29925688 Benign 1/176 0/258
HIRIP3 Pro2 na 92636G.A Het chr16:29915618 na 1/91 0/93
HIRIP3 Pro5 na 93598T.C Het chr16:29914656 na 1/85 0/93
HIRIP3 Exon 5 R419C 61843C.T Het chr16:29912615 Benign 1/179 0/183
MAZ Pro2 na 114496T.G Het chr16:29724343 na 1/92 0/90
PPP4C Pro2 na 14556T.C Het chr16:29993698 na 1/92 0/90
PPP4C Pro2 na 14708T.C Het chr16:29993546 na 1/92 0/90
MAPK3 Exon 2 V63M 133587G.A Het chr16:30040810 Benign 1/91 0/184
SEZ6L2 Pro3 na 62867G.A Het chr16:29818551 na 1/91 0/91
63078G.AH e t
SEZ6L2 Pro4 na 63078G.A Hom chr16:29818340 na 2/86 0/86
SEZ6L2 Exon 2 E38E 64646G.A Hemi
e chr16:29816772 na 1/708 0/556
SEZ6L2 Exon 3 T77T 65494G.A Het chr16:29815924 na 1/527 0/278
SEZ6L2 Exon 7 S396L 74926C.T Het chr16:29806492 Benign 1/1099 0/1152
SEZ6L2 Exon 11 P588L 85179C.T Het chr16:29796239 Benign 1/527 0/278
SEZ6L2 Exon 13 P724L 88933C.T Het chr16:29792485 Benign 1/527 0/554
SEZ6L2 Exon 13 L734Q 88963T.A Het chr16:29792455 Benign 1/527 0/554
SEZ6L2 Exon 16 I887I 90367C.T Het chr16:29791051 na 1/527 0/278
TAOK2 Pro2 na 117019G.A Het chr16:29891235 na 1/91 0/93
TAOK2 Pro2 na 117050G.A Het chr16:29891204 na 2/183 0/457
TAOK2 Pro5 na 115685C.G Het chr16:29892569 na 1/91 0/93
TAOK2 Pro5 na 115775G.A Het chr16:29892479 na 1/91 0/93
TAOK2 Exon 14 A522T 104078G.A Het chr16:29904176 Benign 1/87 0/83
aUTR, untranslated region; Pro, promoter (specific nucleotide position is specified in Table).
bPositions based on the following accession numbers: DOC2A (Q14183); HIRIP3 (Q9BW71); MAPK3 (P27361); SEZ6L2 (Q6UXD5); TAOK2 (Q9UL54).
cPositions based on the following accession numbers: ALDO, DOC2A, HIRIP3, and PPP4C (AC093512.2); MAZ (AC009133); MAPK3 (AC012645.7); SEZ6L2 (AC120114.2);
TAOK2 (AC093512.2).
dHet, heterozygous; Hom, homozygous; Hemi, hemizygous.
eThis patient harbors a 16p11.2 microdeletion.
fBased on UCSC Genome Browser (http://genome.ucsc.edu/), Human March 2006 Assembly.
gBased on PolyPhen (http://genetics.bwh.harvard.edu/pph/).
kNumber of individuals.
doi:10.1371/journal.pone.0004582.t001
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ganglia, amygdala, thalamus and at lower levels in the pons and
putamen (Figure 1C–K). The developmental expression pattern of
SEZ6L2 in mice and humans is consistent with the neurodevel-
opmental basis of autism spectrum disorder [29], thereby
providing further support for a role of SEZ6L2 in autism.
Genetic variation in other 16p11.2 genes
We identified 16 autism-specific rare variants in seven
additional 16p11.2 candidate genes analyzed (Table 1) and 33
control-specific variants (Table S4). Of the autism-specific
variants, five were coding (all non-synonymous), one was located
in the 59 UTR, and ten were promoter variants. One of the coding
variants, M225I, was identified in the synaptic vesicle gene DOC2A
and was predicted to alter protein function. This paternally
inherited variant was also present in an affected sibling but absent
in an unaffected sibling. In addition, M225I was absent in 258
control subjects. The ethnicity of the patient harboring M225I was
indicated as ‘White - Hispanic or Latino’ and most of our controls
are of European descent with no specific information on Hispanic
or Latino ancestry. Therefore, M225I might represent a Hispanic/
Latino-specific variant.
For the promoter variants, we determined nucleotide conser-
vation across several species, performed transcription factor
binding site (TFBS) analyses, and determined transmission and
segregation patterns in families (Table S3 and Table S7). One
Figure 1. SEZ6L2 is expressed in mouse and human central nervous systems. In situ analyses in whole mouse embryos demonstrate that
Sez6l2 mRNA is expressed in the developing brain and spinal cord at e10.5 (A) and e12.5 (B). Human SEZ6L2 transcript distribution was assayed in 18-
and 19-week-old human brains sectioned in either coronal orientation in subjects 1137 (C), 1110 (D, E) and in the sagittal orientation in subject 4889
(F). SEZ6L2 is enriched in the cortical plate in the post mitotic neuron, in the ventricular zone, in the hippocampus, thalamus, ganglionic eminence,
basal ganglia, and amygdala and at lower levels in the pons and the putamen. Emulsion picture of the dentate gyrus showing cellular specificity
within the hippocampus (K). Sense controls tested on adjacent sections (not shown) gave no signal. Am, Amygdala; BG, Basal ganglia; CP, Cortical
plate; DG, Dentate gyrus; GE, Ganglionic eminence; Hi, Hippocampus; Pu, Putamen; Th, Thalamus.
doi:10.1371/journal.pone.0004582.g001
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DOC2A promoter region. This variant was predicted to alter
binding sites for several transcription factors that have established
roles in brain and behavioral development.
We formally assessed the mutation burden of rare variants in
patients versus controls, but did not detect a statistically significant
difference in the total number of autism-specific variants
compared to control-specific variants (Fisher’s exact two tailed
p=0.42). We stratified our analyses by gene as well as by coding
and promoter regions, and did not detect any significant
differences in variant frequencies between patients and controls.
Discussion
We undertook a study of the 16p11.2 microdeletion/duplication
region to investigate the role of common and rare genetic variation
in 16p11.2 loci and risk for autism. Common and complex
diseases such as autism can be due to genetic variation associated
with a wide spectrum of allele frequencies [30]. We hypothesized
that common and/or rare functional variants in one or more genes
in 16p11.2 may confer susceptibility to autism. To elucidate the
potential role of 16p11.2 common genetic variation in autism, we
analyzed existing SNP genotyping data from the following
platforms: Affymetrix 5.0, Illumina 550 K, and Affymetrix
500 K microarrays. Our analysis identified a single nominal
association with rs7193756 that resides in a LD block that contains
the transmembrane protein C16orf54 and the quinolinate
phosphoribosyl-transferase gene QPRT. Overall, our association
analyses indicate that common variation at 16p11.2 is not a major
risk factor in autism. However, we cannot rule out the possibility
that common (functional) variants not represented on the three
commercially available microarrays may be associated with
autism.
We also hypothesized that one or more genes residing within the
16p11.2 region harbor rare variants that increase risk for autism. In
other studies, systematic mutation screening of genes initially
identified through chromosomal, CNV, and/or resequencing
analysis has led to the discovery of rare autism-associated
variants/mutations in several genes, including NLGN3 and NLGN4
at Xp22.3 [31], NRXN1 at 2p16.3 [15,32], SHANK3 at 22q13 [33–
35], and CNTNAP2 at 7q35 [36–38]. In the present study, we
identified an initial significant association between a novel SEZ6L2
coding variant R386H and autism (p=0.014). SEZ6L2 is an
intriguingcandidate given the increasedriskofclinical orsubclinical
epilepsy in autism (,20% of patients) [3]. SEZ6L2 is referred to as a
seizure-related gene because a closely related ortholog, Sez-6,i s
upregulated in response to seizure-inducing reagents in mouse
neurons [39]. The R386H substitution resides within a CUB
domain that is found in functionally diverse developmental proteins
such as Tolloid (involved in dorso-ventral patterning) and A5
(critical for targeting growing axons during nerve innervation) [27].
Our expression studies of mouse and human SEZ6L2 in the
developing embryo demonstrated high CNS-specific levels of brain
expression,aswouldbeexpectedforaneurodevelopmentaldisorder
such as autism [40]. Mice deleted for Sez6l2 do not show any
obvious defects in development or behavior [41]. However, mice
deleted forall three SEZfamilymembers exhibit abnormal behavior
that includes impaired motor coordination [41]. It is possible that
R386H may be necessary but not sufficient to produce autism and
relateddisorders in some patients. Although the data presented here
areinsufficient toimplicatea clearroleforR386H inautism,follow-
up investigations such as additional replication studies and
functional experiments are warranted to evaluate its importance
in disease risk.
Our screen for rare variants in seven additional genes identified
several nucleotide substitutions of potential interest. The M225I
substitution, predicted to affect protein function, was identified in
the brain-specific synaptic vesicle-associated protein DOC2A
(Double C2-Like Domain-Containing Protein, Alpha) that is
thought to serve as a calcium sensor in neurotransmitter release
[42,43]. The M225I substitution is located between the two C2
domains, which interact with Ca
2+ and phospholipids. Mice
deleted for Doc2a show alterations in synaptic transmission and
long-term potentiation and exhibit learning and behavioral deficits
that include an abnormal passive avoidance task [44]. We also
identified a DOC2A promoter variant in another patient that is
predicted to alter transcription factor binding sites for several
brain-expressed genes.
In conclusion, we report an initial analysis of common and rare
genetic variation in the 16p11.2 microdeletion/duplication region
that is associated with ,1% of autism cases. The novel rare variants
identified in this study represent an initial catalog of low frequency,
putative functional risk factors in autism. We do not report
compelling evidence for a role of either common or rare genetic
variants in autism etiology. Our findings might be interpreted to
suggest that deletion and/or duplication of multiple genes in the
16p11.2 interval is a more significant genetic risk factor for
predisposition to autism, rather than molecular risk contributed by
any one gene at this locus. Given that our choice of eight candidate
genes was somewhat biased towards biological function, it is also
possible that other genes or genomic features in the 16p11.2 region
might contribute to autism. Although mutations associated with
autism have been identified by screening as few as several hundred
patients [32,33], one limitation of our study is the relatively small
number of patients screened for rare variants. Additional studies in a
larger numberofpatients forthe genesexamined here are warranted.
In addition, the application of next-generation sequencing strategies
to screen all genes and regulatory elements within the microdeletion/
duplication may reveal more significant abnormalities.
Materials and Methods
Ethics Statement
All research involving humans and animals have been approved
by the Institutional Review Boards of The University of Chicago,
The University of Toronto, and The University of California, Los
Angeles. All families provided written informed consent for the
collection of samples and subsequent analysis.
Autism and Control Subjects
Genomic DNA from autism and control subjects were obtained
from various sources as described below. Ethnic breakdown for all
autism and control groups are provided in Table S5. We obtained
autism samples from several DNA repositories including the
Autism Genetics Resource Exchange (AGRE) (n=793) and the
National Institutes of Mental Health (NIMH) (n=313). For the
AGRE sample set, the Autism Diagnostic Interview–Revised
(ADI-R), Autism Diagnostic Observation Schedule (ADOS),
Raven and Handedness, Peabody and Vineland assessments were
performed. Medical histories and physical neurological exams
were also collected. Additional phenotypic data on the AGRE
sample set are available on the AGRE website (http://www.agre.
org/). Genomic DNA from control subjects were obtained from
the NIMH Genetics Initiative Control sample set (n=1161); these
subjects were screened for any Axis I mental health disorders and
none had a diagnosis of autism.
Genomic DNA was also obtained from several Canadian
institutions including The Hospital for Sick Children in Toronto
16p11 Variation in Autism
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John’s, Newfoundland (n=529). For the Canadian autism cohort,
all subjects met ADI-R and ADOS criteria conclusively or on a
clinical best estimate. Most index patients (,75%) were screened
for fragile6mutations and were karyotyped. Wherever possible,
experiments were performed on blood-derived genomic DNA
(80%); otherwise, DNA from cell lines was used. Control DNA was
isolated from cell lines from the Ontario Population Genomics
Platform (n=570). Subjects living in Ontario, Canada were
recruited by telephone from a list of randomly selected residential
telephone numbers for Ontario and from population-based Tax
Assessment Rolls of the Ontario Ministry of Finance. Health and
Ancestry of these subjects is self reported in an extensive
questionnaire.
Association analyses
Association analyses were performed on existing data generated
on the following three SNP genotyping platforms: 1) Affymetrix
5.0 data available on 777 AGRE families by the Autism
Consortium [21]; 2) IlluminaHap550 data available on 943
AGRE families by the microarray facility at Children’s Hospital of
Philadelphia (www.agre.org/) (Bucan and Hakonarson, unpub-
lished); and 3) Affymetrix 500 K platform data on 60 families [18].
PLINK v1.03 was used for the analysis [45]. Two different types of
analyses were performed. First, we performed the transmission
disequilibrium test (TDT) [24] with permutation for families with
2 genotyped parents and 1 or more affected offspring. The
permutation procedure flips transmitted/untransmitted status
constantly for all SNPs for a given family, thereby preserving the
linkage disequilibrium and linkage information between markers
and siblings. Second, we used DFAM for all individuals. DFAM
within PLINK implements the sib-TDT [25] and also allows for
unrelated individuals to be included (via a clustered-analysis using
the Cochran-Mantel-Haesnzel) and can be used to combine
discordant sibship data, parent-offspring trio data and unrelated
case/control data in a single analysis. Region-wide significance for
both tests was estimated using the mperm option in PLINK which
uses permutation to correct for multiple testing of all the markers
within the region while taking linkage disequilibrium into account.
DNA amplification and sequencing
Genes (accession numbers) examined in this study include:
ALDOA (NM_000034.2), DOC2A (NM_003586.2), HIRIP3
(NM_003609.2), MAPK3 (NM_002746.2), MAZ (NM_002383.2),
PPP4C (NM_002720.1), SEZ6L2 (NM_201575.2), and TAOK2
(NM_004783.2). PCR-amplification primers were designed using
Primer3 (http://frodo.wi.mit.edu/) with M13 Forward and
Reverse Tails added to each primer to facilitate high-throughput
DNA sequencing (Table S8). DNA was amplified in a reaction
comprised of: 20 ng genomic DNA, 16buffer I (1.5 mM MgCl2,
Applied Biosystems, Foster City, CA), 1 mM dNTPs (Applied
Biosystems), 0.4 mM primer (each of forward and reverse, IDT,
Coralville, IA), and 0.25 units AmpliTaq Gold (Applied Biosys-
tems) in a total volume of 10 ml. Thermocycling conditions were as
follows: 94uC for 10 min; 35 cycles of 94uC for 30 sec, annealing
temperature (53–60uC) for 30 sec, and 72uC for 30 sec; and final
extension of 72uC for 10 min. Variations in reaction composition
and cycling conditions were required for a small number of
amplicons. PCR products were purified in a 10 ul reaction
comprised of 6.6 units Exonuclease I and 0.66 units shrimp
alkaline phosphatase that were incubated at 37uC for 30 min
followed by 80uC for 15 minutes. Sequencing reactions were
performed using Big Dye terminators on an ABI 3730XL 96-
capillary automated 3730XL DNA sequencer (Applied Biosys-
tems) at The University of Chicago DNA Sequencing and
Genotyping Core Facility. Sequence data were imported as AB1
files into Mutation Surveyor v3.10 (SoftGenetics, State College,
PA). Sequence contigs were assembled by aligning the AB1 files
against GenBank reference sequence files that were obtained from
the National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov/Genbank/). Reference sequences
included the complete 59 untranslated region (UTR), coding
sequence and associated splice-sites, intronic sequence, and
complete 39 UTR. The imported GenBank files provide annotated
features for each gene that include base count, intron/exon
boundaries, amino acid sequence, and previously reported
mutations and single nucleotide polymorphisms (SNPs) from the
SNP database (dbSNP) (http://www.ncbi.nlm.nih.gov/projects/
SNP/). To screen for putative mutations, the entire length of the
sample trace was manually inspected for quality and variation
from the reference trace. All detected variants were visually
reviewed by two trained individuals and were confirmed using bi-
directional sequencing.
Human and mouse SEZ6L2 expression studies
Mouse in situ hybridization experiments were performed as
previously described [46] on wildtype CD-1 whole embryos using
DIG-labeled RNA probe for Sez6l2 (IMAGE clone 6467632,
Invitrogen). Human in situ hybridization experiments were
performed on fresh frozen post-fixed tissues as previously
described. [47]. The SEZ6L2-specific sequence (MHS1011-
59266) was obtained from OpenBiosystem (Huntsville, AL),
sequenced for verification, and checked for specificity with BLAST
against the human genome. In vitro transcription was then
performed to generate S
35-labeled cRNA. Labeled cRNA was
hybridized on 20 mm thick cryostat frozen tissue sections,
sectioned into either coronal or sagittal plane and opposed to
autoradiography films for two to five days. Slides were then coated
with NTB2 autoradiography emulsion (Kodak, New Haven, CT),
exposed for four weeks, and developed. Following staining with
cresyl violet, emulsion dipped slides were cover-slipped and
imaged using Nikon Eclipse E600 microscope with a Digital
Capture System built around spot cooled CCD camera.
Corresponding sense probes were used on sections adjacent to
those used for antisense probes.
Bioinformatic and statistical analyses
Gene selection was performed using the UCSC Genome
browser (http://genome.ucsc.edu/) and literature review of
articles published in PubMed (http://www.ncbi.nlm.nih.gov/
sites/entrez). PolyPhen was used to predict whether amino acid
substitutions affect protein function. The differences in frequency
of any variant between cases and controls were assessed using the
Fishers Exact test.
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